Help people with cancer
live longer and better.
About us
live longer and better.
Management Team
John Z. Gong,M.D.,Ph.D.
Chairman and CEO
— US FDA Reviewer for 10 years, conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics
— VP of Drug Development and Regulatory Affairs of BeiGene
— With more than 30 years of global industry and academic experience, Dr. John Gong devoted into new drug R&D in different stakeholders from FDA, CRO to biotech companies. He gained rich experience on following field: leading global new drug development, manufacture and commercialization, the process of identifying, license-in and co-development drug candidates, strategic planning for global development, registration and commercialization, pre-clinical and clinical trial designs, GLP/GCP/GMP regulations, project risk management
— Ph.D. degree in Toxicology from New York University in 1996 and medical degree from Beijing Medical College in 1984
— Member of editorial board of Chinese Journal of New Drugs, Progress in Pharmaceutical Sciences and DIA advisory committee, International Innovative Drug Supervision Professional Committee member of the PhIRDA
-
Shen Xiao,M.D.,Ph.D.
Chief Medical Officer— Master in Shanghai Jiao Tong University School of Medicine (formerly Shanghai No.2 Medical University); Ph.D. in Kidney Physiology And Cell Biology, West Virginia University
— Rich and comprehensive experience in new drug review. During his approximately 20-year work in U.S. Food and Drug Administration (FDA), he has been responsible for the various stages of hundreds of reviews for new drugs, and has been in charge of the New Drug Application (NDA) of a dozen new drugs.
-
Jing Zhang / USCPA
Chief Financial Officer— Bachelor’s degree in medical nutrition from Yat-sen University of Medical Sciences; Master in Accountancy, University of South Carolina
— Member of AICPA, worked for United Technologies and Anthem, 20+ years as global healthcare financial management executive in US MNC, health insurance company and big 4 audit firms
-
Fang Xia
Secretary to the Board, Head of Public Relations— Master in Pharmacognosy,Peking University Health Science Center，MBA in Harvard Business School.
— Worked as deputy director of product design center in Taiji Group in Beijing, responsible for product registration and regulatory communication.
-
Yihui Lin, Ph.D.
Vice President, Head of Translational Medicine Center— Ph.D. in Biology, Shanghai Institute of Biochemistry, China Academy of Sciences Shanghai
— Worked for GlaxoSmithKline, experienced in biomarker validation and translational medicine
-
Ming Zhu
Vice President, Head of Company Operations— Bachelor in Finance, Suzhou University
— Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, over 15 years' operation management experience
-
Yue He
Executive Director, Quality Management— Master in Clinical Medicine in Sichuan University, MBA in Hong Kong Asia Business College
— Worked for BeiGene, Ronggang Biotechnology Pharma and Baitai Biopharmaceutical, 13 years of experience in the pharmaceutical industry。
-
R&D team 
Jian Zhou, Ph.D.
Vice President, Small Molecule CMC— Master in Medicinal Chemistry, Peking University; Ph.D. in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland
— Comprehensive experience in drug R&D, manufacturing, quality research and the construction of pharmaceutical plants
-
111 
Qiang Feng, Ph.D.
Senior Director, Biopharmaceutical CMC— Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D. in Cell Biology, Fourth Military Medical University
— Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R&D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects
-
Shen Xiao,M.D.,Ph.D.
Chief Medical Officer— Master in Shanghai Jiao Tong University School of Medicine (formerly Shanghai No.2 Medical University); Ph.D. in Kidney Physiology And Cell Biology, West Virginia University
— Rich and comprehensive experience in new drug review. During his approximately 20-year work in U.S. Food and Drug Administration (FDA), he has been responsible for the various stages of hundreds of reviews for new drugs, and has been in charge of the New Drug Application (NDA) of a dozen new drugs.
-
Jing Zhang / USCPA
Chief Financial Officer— Bachelor’s degree in medical nutrition from Yat-sen University of Medical Sciences; Master in Accountancy, University of South Carolina
— Member of AICPA, worked for United Technologies and Anthem, 20+ years as global healthcare financial management executive in US MNC, health insurance company and big 4 audit firms
-
Fang Xia
Secretary to the Board, Head of Public Relations— Master in Pharmacognosy,Peking University Health Science Center，MBA in Harvard Business School.
— Worked as deputy director of product design center in Taiji Group in Beijing, responsible for product registration and regulatory communication
-
Yihui Lin, Ph.D.
Vice President, Head of Translational Medicine Center—Ph.D. in Biology, Shanghai Institute of Biochemistry, China Academy of Sciences Shanghai
— Worked for GlaxoSmithKline and the Institute of Health Sciences, experienced in biomarker validation and translational medicine
-
Ming Zhu
Vice President, Head of Company Operations— Bachelor in Finance, Suzhou University
— Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, over 15 years' operation management experience
-
Yue He
Senior Director of the Quality Management— Master in Clinical Medicine in Sichuan University, MBA in Hong Kong Asia Business College
— Worked for BeiGene, Ronggang Biotechnology Pharma and Baitai Biopharmaceutical, 13 years of experience in the pharmaceutical industry
-
Jian Zhou, Ph.D.
Vice President, Small Molecule CMC— Master in Medicinal Chemistry, Peking University; Ph.D. in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland
— Comprehensive experience in drug R&D, manufacturing, quality research and the construction of pharmaceutical plants
-
Qiang Feng, Ph.D.
Senior Director, Biopharmaceutical CMC— Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D in Cell Biology, Fourth Military Medical University
— Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R&D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects.
